Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan by Shuji Uno, Shuichi Midorikawa, Kei Inoue, Daisuke Ichikawa, Tomoki Ito, Junya Kuroda, Kenshi Suzuki

“…We extracted EMRs in the Real World Data (RWD) database of patients with a confirmed diagnosis of MM and treatment history with bortezomib, thalidomide, and/or lenalidomide. OS and prognostic factors for OS were analyzed using a univariate analysis and decision tree model. …”
Get full text

Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan. by Shuji Uno, Shuichi Midorikawa, Kei Inoue, Daisuke Ichikawa, Tomoki Ito, Junya Kuroda, Kenshi Suzuki

“…We extracted EMRs in the Real World Data (RWD) database of patients with a confirmed diagnosis of MM and treatment history with bortezomib, thalidomide, and/or lenalidomide. OS and prognostic factors for OS were analyzed using a univariate analysis and decision tree model. …”
Get full text

Combined Use of Ninjin'yoeito Improves Subjective Fatigue Caused by Lenalidomide in Patients With Multiple Myeloma: A Retrospective Study by Tomoki Ito, Akiko Konishi, Yukie Tsubokura, Yoshiko Azuma, Masaaki Hotta, Hideaki Yoshimura, Takahisa Nakanishi, Shinya Fujita, Aya Nakaya, Atsushi Satake, Kazuyoshi Ishii, Shosaku Nomura

“…Lenalidomide is an immunomodulating derivative of thalidomide, which shows anti-tumor activity against myeloma cells with immunomodulation including augmentation of T-cell and natural killer cell function. …”
Get full text